Colleran David 4

What Happened

• David Colleran, EVP, General Counsel and Corporate Secretary of Anika Therapeutics (ANIK), had the third and final installment of an RSU award vest on March 9, 2026. The award converted 5,465 restricted stock units into common shares.
• To satisfy tax withholding on the vested RSUs, 1,919 shares were retained by the company at $14.96 per share, totaling $28,708. The remaining shares were issued to Colleran.

Key Details

• Transaction date: March 9, 2026; Form filed March 11, 2026 (timely).
• Vesting: 5,465 RSUs converted to common stock (third and final installment of a 16,395 RSU grant made 3/9/2023).
• Tax withholding: 1,919 shares withheld/disposed to cover tax liability at $14.96 per share for a total withholding value of $28,708 (footnote F3).
• Other notes: Footnote F1 confirms each RSU converts to one share; footnote F2 notes Colleran also acquired 1,600 shares via the company ESPP in 2025 (800 on 5/14/2025 and 800 on 11/14/2025).
• Shares owned after the transaction: Not specified in the provided filing excerpt.

Context

• This was an RSU vesting event (award conversion), not an open-market purchase or a discretionary sale. The withholding of shares to cover taxes is a routine administrative action and does not necessarily indicate a buy/sell view on the stock.
• The filing shows a cashless share withholding to satisfy tax obligations rather than a separate cash payment.